International Psoriasis Council

Advancing Knowledge. Improving Care.

Advancing Knowledge. Improving Care.

Commentary: Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19

computer with words expert commentary

Francesca Capon, PhD
King’s College London
London, UK
IPC Councilor


Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. Matthew T. Patrick, MEng PhD, Haihan Zhang, MS, Rachael Wasikowski, MS, Errol P. Prens, MD, PhD, Stephan Weidinger, MD, PhD, Johann E. Gudjonsson, MD, PhD, James T. Elder, MD, PhD, Kevin He, PhD, and Lam C. Tsoi, PhD. J Allergy Clin Immunol. 2021 Jan 21 doi: 10.1016/j.jaci.2021.01.006 [Epub ahead of print]


Genetic studies suggest that inflammatory skin diseases increase the risk of COVID-19.

An article recently published in the Journal of Allergy and Clinical Immunology1 suggests that diseases such as psoriasis and atopic dermatitis increase the risk of COVID-19 by approximately 50%. The authors of the study (Lam Tsoi and collaborators, University of Michigan) examined the medical records of 435,000 individuals, 1115 of whom had been diagnosed with COVID-19. After adjusting their analysis for the age, ethnicity, body mass index, and socioeconomic status of participants, they found that having an inflammatory skin disorder (acne, atopic dermatitis, or psoriasis) conferred an increased risk of COVID-19 while reducing the likelihood of requiring mechanical ventilation.

The authors next analyzed publicly available expression data and observed a significant overlap between the genes that are up-regulated in inflammatory skin diseases and those that are induced by SARS-CoV2 infection in bronchial epithelial cells. Of note, the shared genes were mostly involved in epidermal barrier function and innate antiviral responses.

In the final stage of the study, the authors re-examined published genome-wide association studies and found a marker that was associated with susceptibility to both psoriasis and COVID-19. Interestingly, the variant maps in proximity to S100A12, a gene that is up-regulated in psoriatic lesions and in SARS-CoV2 infected cells.

These observations suggest a link between skin inflammation and COVID-19 susceptibility. The authors speculate that in individuals with psoriasis or atopic dermatitis, SARS-CoV2 could enter the organism through the skin, exploiting defects in epidermal barrier function. Progression to severe disease would then be hindered by the activation of immune responses at sites of inflammation. While these hypotheses could be tested in animal models, the authors acknowledge that the underlying observations will need to be replicated in further genetic and epidemiological studies.


Associations between COVID-19 and skin conditions identified through epidemiology and genomic studies. MT Patrick et al. J Allergy Clin Immunol. Epub ahead of print: 20th Jan 2021. DOI:


Recent Posts

Remembering Dr. Hoseah Waweru: A Beacon of Hope and Inspiration in the Fight Against Psoriasis

Psoriasis in Older Patients: Key Considerations and Best Practices for Effective Management

Getting to Know IPC’s Board Member Lone Skov: What Inspired Me to Specialize in Psoriasis

Also Read

Biological agents for psoriasis

Commentary: An Oral Interleukin-23-Receptor Antagonist Peptide for Plaque Psoriasis

This commentary provides expert analysis on recent research findings, clinical trial results, and the promising future of therapies for individuals with moderate to severe plaque psoriasis. Uncover the latest advancements in psoriasis treatments, focusing on the significant impact of new biological agents and oral IL-23 receptor antagonists.

Read More
Commentary -Tiago Torres
Psoriatic inflammation

Commentary: Single-cell and Spatial Transcriptomics Analysis of Psoriasis Skin Lesions After IL-23 Inhibition

Gain expert insights into two recent publications shedding light on the molecular mechanisms of IL-23/IL-17 axis-targeting biologic therapies for psoriasis treatment. The commentary discusses longitudinal single-cell and spatial transcriptomics analyses, revealing early drug actions and genetic factors influencing clinical responses.

Read More

Subscribe to the IPC Newsletter

Stay up-to-date on the latest research, news, and upcoming events right in your inbox.